Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?

Stem Cells

Volumn 32, Issue 9, 2014, Pages 2430-2442

  Moll, Guido ^a   Alm, Jessica J ^a   Davies, Lindsay C ^b   Von Bahr, Lena ^a   Heldring, Nina ^a   Stenbeck Funke, Lillemor ^c   Hamad, Osama A ^c   Hinsch, Robin ^a   Ignatowicz, Lech ^d   Locke, Matthew ^b   Lönnies, Helena ^a   Lambris, John D ^e   Teramura, Yuji ^c,f   Nilsson Ekdahl, Kristina ^c   Nilsson, Bo ^c   Le Blanc, Katarina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bone marrow stromal cells; Cellular therapy; Clinical translation; Cryopreservation; Engraftment; Immunotherapy; Instant blood mediated inflammatory reaction

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3A; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; APOPTOSIS; ARTICLE; CELL COUNT; CELL CULTURE; CELL SIZE; CELL STRUCTURE; CELL VIABILITY; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTINUOUS CULTURE; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE RELEASE; CYTOLYSIS; FEMALE; FLOW CYTOMETRY; FREEZE THAWING; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; INSTANT BLOOD MEDIATED INFLAMMATORY REACTION; MALE; MEMBRANE DAMAGE; MESENCHYMAL STROMA CELL; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; WESTERN BLOTTING; ADOLESCENT; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; CYTOLOGY; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INFANT; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PRESCHOOL CHILD; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CRYOPRESERVATION; FEMALE; HUMANS; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INFANT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; YOUNG ADULT;

EID: 84906275192     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1729     Document Type: Article

References (42)

1. Ankrum J, Karp JM,. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010; 16: 203-209.
2. Wagner B, Henschler R,. Fate of intravenously injected mesenchymal stem cells and significance for clinical application. Adv Biochem Eng/Biotechnol 2013; 130: 19-37.
3. Bianco P, Barker R, Brustle O, et al. Regulation of stem cell therapies under attack in Europe: For whom the bell tolls. EMBO J 2013; 32: 1489-1495.
4. Bianco P, Cao X, Frenette PS, et al. The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nat Med 2013; 19: 35-42.
5. Galipeau J,. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 2013; 15: 2-8.
6. Francois M, Copland IB, Yuan S, et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 2012; 14: 147-152.
7. Quimby JM, Webb TL, Habenicht LM, et al. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: Results of three sequential pilot studies. Stem Cell Res Ther 2013; 4: 48.
8. von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012; 30: 1575-1578.
9. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932-8937.
10. Moll G, Rasmusson-Duprez I, von Bahr L, et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 2012; 30: 1565-1574.
11. Stephenne X, Nicastro E, Eeckhoudt S, et al. Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity. PLoS One 2012; 7: e42819.
12. Tatsumi K, Ohashi K, Matsubara Y, et al. Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism. Biochem Biophys Res Commun 2013; 431: 203-209.
13. Moll G, Hult A, von Bahr L, et al. Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells? PLoS One 2014; 9: e85040.
14. Nilsson B, Korsgren O, Lambris JD, et al. Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol 2010; 31: 32-38.
15. Moll G, Jitschin R, von Bahr L, et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS One 2011; 6: e21703.
16. Li Y, Lin F,. Mesenchymal stem cells are injured by complement after their contact with serum. Blood 2012; 120: 3436-3443.
17. Soland MA, Bego M, Colletti E, et al. Mesenchymal stem cells engineered to inhibit complement-mediated damage. PLoS One 2013; 8: e60461.
18. Ankrum JA, Ong JF, Karp JM,. Mesenchymal stem cells: Immune evasive, not immune privileged. Nat Biotechnol 2014; 32: 252-260.
19. Alagesan S, Griffin MD,. Autologous and allogeneic mesenchymal stem cells in organ transplantation: What do we know about their safety and efficacy? Curr Opin Organ Transplant 2014; 19: 65-72.
20. Ricklin D, Hajishengallis G, Yang K, et al. Complement: A key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-797.
21. Roos A, Xu W, Castellano G, et al. Mini-review: A pivotal role for innate immunity in the clearance of apoptotic cells. Eur J Immunol 2004; 34: 921-929.
22. Kemper C, Atkinson JP, Hourcade DE,. Properdin: Emerging roles of a pattern-recognition molecule. Ann Rev Immunol 2010; 28: 131-155.
23. Mevorach D, Trahtemberg U, Krispin A, et al. What do we mean when we write "senescence," "apoptosis," "necrosis," or "clearance of dying cells"? Ann N Y Acad Sci 2010; 1209: 1-9.
24. Nauta AJ, Roos A, Daha MR,. A regulatory role for complement in innate immunity and autoimmunity. Int Arch Allergy Immunol 2004; 134: 310-323.
25. Giles KM, Hart SP, Haslett C, et al. An appetite for apoptotic cells? Controversies and challenges. Br J Haematol 2000; 109: 1-12.
26. Green DR, Ferguson T, Zitvogel L, et al. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9: 353-363.
27. Saas P, Gaugler B, Perruche S,. Intravenous apoptotic cell infusion as a cell-based therapy toward improving hematopoietic cell transplantation outcome. Ann N Y Acad Sci 2010; 1209: 118-126.
28. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11-20.
29. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371: 1579-1586.
30. Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007; 21: 1733-1738.
31. Vermes I, Haanen C, Steffens-Nakken H, et al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184: 39-51.
32. Ekdahl KN, Hong J, Hamad OA, et al. Evaluation of the blood compatibility of materials, cells, and tissues: Basic concepts, test models, and practical guidelines. Adv Exp Med Biol 2013; 735: 257-270.
33. Davies LC, Lonnies H, Locke M, et al. Oral mucosal progenitor cells are potently immunosuppressive in a dose-independent manner. Stem Cells Dev 2012; 21: 1478-1487.
34. Pal R, Hanwate M, Totey SM,. Effect of holding time, temperature and different parenteral solutions on viability and functionality of adult bone marrow-derived mesenchymal stem cells before transplantation. J Tissue Eng Regen Med 2008; 2: 436-444.
35. Ginis I, Grinblat B, Shirvan MH,. Evaluation of bone marrow-derived mesenchymal stem cells after cryopreservation and hypothermic storage in clinically safe medium. Tissue Eng Part C, Methods 2012; 18: 453-463.
36. Galvez-Martin P, Hmadcha A, Soria B, et al. Study of the stability of packaging and storage conditions of human mesenchymal stem cell for intra-arterial clinical application in patient with critical limb ischemia. Eur J Pharm Biopharm 2014; 86: 459-468.
37. Sohn HS, Heo JS, Kim HS, et al. Duration of in vitro storage affects the key stem cell features of human bone marrow-derived mesenchymal stromal cells for clinical transplantation. Cytotherapy 2013; 15: 460-466.
38. Jungebluth P, Moll G, Baiguera S, et al. Tissue-engineered airway: A regenerative solution. Clin Pharmacol Therap 2012; 91: 81-93.
39. Samuelsson H, Ringden O, Lonnies H, et al. Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy 2009; 11: 129-136.
40. Singer NG, Caplan AI,. Mesenchymal stem cells: Mechanisms of inflammation. Ann Rev Pathol 2011; 6: 457-478.
41. Doorn J, Moll G, Le Blanc K, et al. Therapeutic applications of mesenchymal stromal cells: Paracrine effects and potential improvements. Tissue Eng Part B, Rev 2012; 18: 101-115.
42. von Bahr L, Sundberg B, Lonnies L, et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012; 18: 557-564.